Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'

Description:

Description
  • Accession: P51160
  • Swissprot: PDE6C_HUMAN
  • Organism: Homo sapiens
  • Gene: PDE6C
  • Target class: Enzyme

Drug Relations:

dipyridamole
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Bioactivity details MOA
avanafil
a selective inhibitor of cGMP-specific PDE5 has no direct relaxant effect on isolated human corpus cavernosum, but enhances the effect of NO by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum Bioactivity details MOA
sildenafil
A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION. Bioactivity details MOA
tadalafil
A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION. Bioactivity details MOA